how big is Balaxi Pharma?

As of Jun 06, Balaxi Pharmaceuticals Ltd has a market capitalization of 286.75 Cr, with recent net sales of 292.56 Cr and net profit of 25.07 Cr over the last four quarters. Shareholder's funds are 201.36 Cr, and total assets are valued at 258.34 Cr as of Mar'24.

Market Cap: Balaxi Pharmaceuticals Ltd has a market capitalization of 286.75 Cr and is classified as a Micro Cap company as of Jun 06.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Mar'25, Dec'24, Sep'24, and Jun'24, is 292.56 Cr. The sum of Net Profit for the same period is 25.07 Cr. This data is consolidated.<BR><BR>Balance Sheet Snapshot: This is consolidated data for the latest annual period ending Mar'24. The Shareholder's Funds amount to 201.36 Cr, and the Total Assets are valued at 258.34 Cr.

What does Balaxi Pharma do?

Balaxi Pharmaceuticals Ltd, a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reported net sales of 76 Cr and a net profit of 9 Cr for the quarter ending March 2025. The company, originally founded in 1942, has a market cap of Rs 287 Cr and a P/E ratio of 11.00.

Overview: <BR>Balaxi Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated in 1942 under the name 'The Anandam Rubber Company Limited' and changed its name to 'Balaxi Ventures Limited' on August 8, 2017. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 76 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 9 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 287 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 11.00 <BR>Industry P/E: 23 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.23 <BR>Return on Equity: 10.82% <BR>Price to Book: 1.22 <BR><BR>Contact Details: <BR>Address: 41/298-D2 2nd Flr Saniya Plaza, Mahakavi Bharatiyar Road Cochin Kerala : 682035 <BR>Tel: 91-484-4032952/6596725 <BR>Email: secretarial@anandamrubberco.com <BR>Website: http://www.balaxipharma.in

When is the next results date for Balaxi Pharma?

No Upcoming Board Meetings

Has Balaxi Pharma declared dividend?

Balaxi Pharmaceuticals Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of July 1, 2022. Despite this, the company has experienced significant volatility, showing negative total returns in shorter periods, while the 5-year period reflects a positive return of 138.34%.

Balaxi Pharmaceuticals Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 01 Jul 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -38.66%, the dividend return was 0%, resulting in a total return of -38.66%.<BR><BR>For the 1-year period, the price return was -51.55%, the dividend return was 0%, leading to a total return of -51.55%.<BR><BR>Over the 2-year period, the price return was -51.61%, with a dividend return of 0%, culminating in a total return of -51.61%.<BR><BR>In the 3-year period, the price return was -37.85%, the dividend return was 0.68%, resulting in a total return of -37.17%.<BR><BR>For the 4-year period, the price return was -57.93%, the dividend return was 0.43%, leading to a total return of -57.5%.<BR><BR>In the 5-year period, the price return was 136.37%, with a dividend return of 1.97%, culminating in a total return of 138.34%.<BR><BR>Overall, Balaxi Pharmaceuticals Ltd has declared a dividend, but the total returns over the various periods indicate significant volatility, with negative returns dominating in the shorter time frames, while the 5-year period shows a substantial positive return.

Who are the peers of the Balaxi Pharma?

Balaxi Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Sun Pharma and Cipla show excellent management and growth, while Divi's Lab has the highest 1-year return at 51.96%, compared to Balaxi Pharma's 0.00%.

Peers: The peers of Balaxi Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Natural Capsules, Coral Labs., Kimia Bioscien., Pharmaids Pharma, and Alpa Laboratorie.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, while Below Average management risk is found at Natural Capsules, Coral Labs., Kimia Bioscien., Pharmaids Pharma, and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted for Divi's Lab., Torrent Pharma, Kimia Bioscien., Pharmaids Pharma, and the rest. Excellent capital structure is seen at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, and Alpa Laboratorie, while Good capital structure is found at Torrent Pharma, Natural Capsules, Coral Labs., and the rest.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Natural Capsules has the lowest at -20.72%. Balaxi Pharma's 1-year return is 0.00%, which is lower than both of these peers. Additionally, the six-month return is negative for Natural Capsules, Coral Labs., and Pharmaids Pharma.

What is the technical trend for Balaxi Pharma?

As of April 21, 2025, Balaxi Pharma's technical trend has shifted to a moderate bearish stance, driven by bearish MACD, moving averages, and KST indicators, despite some divergence in the RSI and mildly bearish Bollinger Bands.

As of 21 April 2025, the technical trend for Balaxi Pharma has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on both weekly and monthly time frames, bearish moving averages on the daily chart, and a bearish KST on both weekly and monthly time frames. The RSI shows no signal on the weekly but is bullish on the monthly, indicating some divergence. Bollinger Bands are mildly bearish on both weekly and monthly charts, while the Dow Theory indicates a mildly bearish trend on the weekly and no trend on the monthly. Overall, the bearish signals dominate the current technical outlook.

Who are in the management team of Balaxi Pharma?

As of March 2023, the management team of Balaxi Pharma includes Ashish Maheshwari (Chairman/Executive Director), Minoshi Maheshwari (Non-Executive Director), and five Independent Non-Executive Directors: Kunal M Bhakta, Gandhi Gamji, M. Srinivas Rao, and Purnima Singh Kamble.

As of March 2023, the management team of Balaxi Pharma includes the following individuals:<BR><BR>1. Ashish Maheshwari - Chairman / Executive Director<BR>2. Minoshi Maheshwari - Non Executive Director<BR>3. Kunal M Bhakta - Independent Non Executive Director<BR>4. Gandhi Gamji - Independent Non Executive Director<BR>5. M. Srinivas Rao - Independent Non Executive Director<BR>6. Purnima Singh Kamble - Independent Non Executive Director

Who are the top shareholders of the Balaxi Pharma?

The top shareholders of Balaxi Pharma include Balaxi Overseas Private Limited with 63.4%, foreign institutional investors holding 16.02%, and Unico Global Opportunities Fund Limited as the largest public shareholder at 8.29%. Individual investors own 9.82%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Balaxi Pharma include the promoters, with Balaxi Overseas Private Limited holding the largest share at 63.4%. Additionally, foreign institutional investors (FIIs) collectively hold 16.02%, with three FIIs involved. The highest public shareholder is Unico Global Opportunities Fund Limited, which owns 8.29%. Individual investors account for 9.82% of the company's shares. There are no pledged promoter holdings, and no mutual funds currently hold shares in the company.

Are Balaxi Pharma latest results good or bad?

Balaxi Pharma's latest Q2 FY26 results are concerning, showing a 95.42% decline in net profit to ₹0.21 crores and a 27.40% drop in revenue to ₹56.18 crores, marking the lowest quarterly revenue in recent history. Overall, these results indicate significant operational challenges and a troubling trend for the company.

Balaxi Pharma's latest results for Q2 FY26 are concerning and indicate a significant decline in performance. The company reported a net profit of just ₹0.21 crores, which is a staggering 95.42% decrease year-on-year. Revenue also fell sharply by 27.40% to ₹56.18 crores compared to the same quarter last year, marking the lowest quarterly revenue in recent history.<BR><BR>The operating margin has drastically dropped to 2.08%, down from 13.67% a year ago, reflecting severe operational challenges. Additionally, the profit before tax margin has shrunk to a mere 2.46%, compared to 7.19% in the previous year. This deterioration in financial metrics raises serious questions about the sustainability of Balaxi's business model.<BR><BR>Overall, the results suggest a troubling trend for the company, with significant revenue and profit declines, indicating that the latest results are indeed bad.

How has been the historical performance of Balaxi Pharma?

Balaxi Pharma's historical performance shows fluctuating net sales and profits, with net sales increasing to 292.56 Cr in March 2025 but profits declining, resulting in a profit after tax of 25.07 Cr. The company faces challenges in cash generation, as indicated by negative cash flow from operating activities.

Answer:<BR>The historical performance of Balaxi Pharma shows a fluctuating trend in net sales and profits over the years, with a notable increase in recent periods.<BR><BR>Breakdown:<BR>Balaxi Pharma's net sales reached 292.56 Cr in March 2025, up from 241.29 Cr in March 2024, but down from 336.43 Cr in March 2023. The total operating income followed a similar pattern, peaking at 336.43 Cr in March 2023 before declining to 292.56 Cr in March 2025. The company's total expenditure, excluding depreciation, was 255.35 Cr in March 2025, which was an increase from 194.56 Cr in March 2024 but lower than 279.90 Cr in March 2023. Operating profit (PBDIT) decreased to 33.49 Cr in March 2025 from 44.08 Cr in March 2024, reflecting a declining operating profit margin of 12.72%. Profit before tax also saw a decline to 28.67 Cr in March 2025 from 40.31 Cr in March 2024, leading to a profit after tax of 25.07 Cr in March 2025, down from 35.91 Cr in March 2024. The company's total assets increased to 310.34 Cr in March 2025, up from 258.34 Cr in March 2024, while total liabilities also rose to 310.34 Cr from 258.34 Cr. Cash flow from operating activities turned negative at -35.00 Cr in March 2025, contrasting with a positive cash flow of 4.00 Cr in March 2024, indicating challenges in cash generation. Overall, Balaxi Pharma's financial performance reflects volatility with a recent trend of declining profits despite increased sales.

How has been the historical performance of Balaxi Pharma?

Balaxi Pharma's historical performance shows fluctuating financial metrics, with net sales increasing to 292.56 Cr in March 2025 from 241.29 Cr in March 2024, but declining from 336.43 Cr in March 2023. Profit after tax also decreased to 25.07 Cr in March 2025, down from 35.91 Cr in March 2024 and 45.96 Cr in March 2023.

Answer:<BR>The historical performance of Balaxi Pharma shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Balaxi Pharma's net sales reached 292.56 Cr in March 2025, an increase from 241.29 Cr in March 2024, but a decline from 336.43 Cr in March 2023. Total operating income mirrored this trend, with 292.56 Cr in March 2025 compared to 241.29 Cr in March 2024 and 336.43 Cr in March 2023. The company's total expenditure, excluding depreciation, was 255.35 Cr in March 2025, rising from 194.56 Cr in March 2024 but down from 279.90 Cr in March 2023. Operating profit (PBDIT) decreased to 33.49 Cr in March 2025 from 44.08 Cr in March 2024 and 59.17 Cr in March 2023. Profit before tax also declined to 28.67 Cr in March 2025 from 40.31 Cr in March 2024 and 56.92 Cr in March 2023, leading to a profit after tax of 25.07 Cr in March 2025, down from 35.91 Cr in March 2024 and 45.96 Cr in March 2023. The company's total assets increased to 310.34 Cr in March 2025 from 258.34 Cr in March 2024, while total liabilities also rose to 310.34 Cr in March 2025 from 258.34 Cr in March 2024. Cash flow from operating activities showed a negative trend, with -35.00 Cr in March 2025 compared to 4.00 Cr in March 2024, while cash and cash equivalents decreased to 39.00 Cr in March 2025 from 62.00 Cr in March 2024.

Should I buy, sell or hold Balaxi Pharma?

Is Balaxi Pharma overvalued or undervalued?

As of November 27, 2025, Balaxi Pharma is considered very attractive and undervalued with a PE ratio of 14.36, significantly lower than its peers like Bajaj Finance and Bajaj Finserv, despite a 53.22% decline in stock performance over the past year.

As of 27 November 2025, Balaxi Pharma's valuation grade has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued, with a PE ratio of 14.36, an EV to EBIT of 11.30, and an EV to EBITDA of 10.33. These ratios suggest that Balaxi Pharma is trading at a lower valuation compared to its peers, particularly when compared to Bajaj Finance, which has a PE ratio of 35.15, and Bajaj Finserv, with a PE ratio of 34.78.<BR><BR>In the context of its industry, Balaxi Pharma's Price to Book Value stands at 0.87, which further reinforces its undervaluation relative to competitors like Life Insurance, which has a PE ratio of 11.14 and an EV to EBITDA of 9.18. Despite recent stock performance showing a decline of 53.22% over the past year compared to a 7.99% increase in the Sensex, the current valuation metrics position Balaxi Pharma as an attractive investment opportunity moving forward.

Why is Balaxi Pharma falling/rising?

As of 18-Dec, Balaxi Pharmaceuticals Ltd's stock price is at Rs. 28.11, having fallen to a new 52-week low of Rs. 27.5, indicating a bearish trend and declining investor interest. The company has shown weak financial fundamentals, with a significant decline in profits and reduced institutional investment, contributing to the stock's downward pressure.

As of 18-Dec, Balaxi Pharmaceuticals Ltd's stock price is falling, currently at Rs. 28.11, reflecting a decrease of Rs. 0.71 or 2.46%. The stock has hit a new 52-week low of Rs. 27.5 today, indicating significant downward pressure. Over the past week, the stock has underperformed the sector by 2.72% and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which suggests a persistent bearish trend.<BR><BR>Investor participation has also declined sharply, with delivery volume dropping by 85.37% compared to the 5-day average, indicating a lack of interest from investors. Furthermore, institutional investors have reduced their stake by 5.37% in the last quarter, which may signal a lack of confidence in the company's future performance.<BR><BR>Financially, Balaxi Pharma has shown weak long-term fundamentals, with a -4.77% compound annual growth rate (CAGR) in operating profits and a significant decline in profits of 56.1% over the past year. The company's net sales are at their lowest, and the negative results reported for the quarter ending September 25 further exacerbate concerns, with a profit after tax of Rs. 9.14 crore reflecting a growth decline of 56.40%.<BR><BR>Overall, the combination of poor financial performance, declining investor participation, and consistent underperformance against benchmarks over the past three years contributes to the stock's falling price.

Which are the latest news on Balaxi Pharma?